drugset
drugset / Trial / NCT04135417

Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for Dialysis

NCT04135417 ↗

Phase 2 Completed 30 enrolled Humacyte, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 2, prospective, multicenter, open-label, single-arm study of the Human Acellular Vessel (HAV).

Timeline

Start
2019-11-12
Primary completion
2021-05-15
Completion
2022-03-02

Drugs

EvaluationDrugModalityDoseRoute
Subject HAV Other / unclassified — —

Indications

end stage renal failure kidney failure